WebPurpose: Although moderate- to high-intensity statin therapy is increasingly recommended in cardiovascular disease patients, the efficacy and safety in elderly patients have not … Web29 de abr. de 2024 · Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol (LDL-C) levels (≥190 mg/dL), …
Secondary Prevention for Atherosclerotic Cardiovascular …
Web28 de mar. de 2024 · In total, 45.6% of the overall high-risk patients did not require the LLT; 43.1% required statin monotherapy; 6.5% statin and ezetimibe; and 4.8% add-on evolocumab. And 75.5% of the overall very-high risk patients required statin monotherapy; 13.2% statin and ezetimibe; and 11.3% add-on evolocumab. WebIn persons 40 to 75 years of age without clinical ASCVD or diabetes and with an estimated 10-year ASCVD risk of 7.5% or greater, moderate- to high-intensity statin therapy … optimus prime knight armor
Natural Language Processing to Identify Reasons for Sex Disparity …
WebHigh-intensity statins are recommended for 2 categories of patients: those with ASCVD (secondary prevention) and high-risk patients without clinical ASCVD. Most patients with ASCVD are candidates for high-intensity statins, with a goal for low-density lipoprotein cholesterol reduction of 50% or greater. Web28 de mar. de 2024 · Disparities in statin use persist in high-risk Americans. Publish date: March 28, 2024. By ... The study divided ASCVD risk strata into three groups – 5% to … Web12 de abr. de 2024 · Moderate-intensity statin with ezetimibe combination therapy was associated with lower rates of intolerance-related drug discontinuation or dose reduction among patients aged ≥75 years (2.3% vs. 7.2%; p = 0.010) and those aged <75 years (5.2% vs. 8.4%; p < 0.001) (p for interaction = 0.159). Median LDL-C levels were 58 mg/dL in … portland table pads